Cargando…

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis

OBJECTIVE: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs, such as MTX, has demonstrated improvement in clinical outcomes in patients with RA. The primary objective of this post hoc analysis was to compare the efficacy of sarilumab (200 mg every 2 weeks) monotherapy (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmester, Gerd R, Bykerk, Vivian P, Buch, Maya H, Tanaka, Yoshiya, Kameda, Hideto, Praestgaard, Amy, van Hoogstraten, Hubert, Fernandez-Nebro, Antonio, Huizinga, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157062/ https://www.ncbi.nlm.nih.gov/pubmed/34508594 http://dx.doi.org/10.1093/rheumatology/keab676

Ejemplares similares

Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab
por: Choy, Ernest, et al.
Publicado: (2022)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
por: Huizinga, Thomas, et al.
Publicado: (2023)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2022)

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
por: Genovese, Mark C., et al.
Publicado: (2020)

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
por: Wells, Alvin F., et al.
Publicado: (2019)

Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
por: Curtis, Jeffrey R., et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
por: Rehberg, Markus, et al.
Publicado: (2021)

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
por: Genovese, Mark C, et al.
Publicado: (2018)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
por: Rehberg, Markus, et al.
Publicado: (2021)

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
por: Choy, Ernest, et al.
Publicado: (2019)

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
por: Fleischmann, Roy, et al.
Publicado: (2017)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
por: Gabay, Cem, et al.
Publicado: (2020)

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
por: Lee, Eun Bong, et al.
Publicado: (2016)

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up
por: Fleischmann, Roy, et al.
Publicado: (2020)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
por: Burmester, Gerd R, et al.
Publicado: (2019)

Sarilumab: Cytomegalovirus colitis: case report
Publicado: (2020)

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
por: Fournier, Marie, et al.
Publicado: (2019)

Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis
por: Boyapati, Anita, et al.
Publicado: (2020)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
por: Vacchi, Caterina, et al.
Publicado: (2020)

Sarilumab: Perforated duodenal ulcer: case report
Publicado: (2021)

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
por: Boyapati, Anita, et al.
Publicado: (2016)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
por: Sainz, Luis, et al.
Publicado: (2023)

Sarilumab use in severe SARS-CoV-2 pneumonia
por: Gremese, Elisa, et al.
Publicado: (2020)

Sarilumab: Thrombocytopenia during an off-label use: case report
Publicado: (2020)

Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
por: Chamlagain, Rajan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uh8sbcp0iuovb4pme5jt7dc6mi